1. Evaluation of the antitumor activity of gemcitabine;Hertel;Cancer Res,1990
2. Comparison of cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-d-arabino-furanosylcytosine;Heihemann;Cancer Res,1988
3. A phase I trial of gemcitabine (LY188011) administered intravenously every two weeks;Brown,1991
4. Difluorodeoxycytidine (dFdC): a phase I study;Poplin,1989
5. Phase I study of 2′,2′-difluorodeoxycytidine (LY188011; dFdC) using an intermittent schedule;Clavel,1989